|
|
|
|
|
|
Sponsors and Collaborators: |
Seoul National University Hospital Abbott Boston Scientific Corporation |
Information provided by: | Seoul National University Hospital |
ClinicalTrials.gov Identifier: | NCT00698607 |
Objectives
Study Design: Prospective, open label, two-arm, randomized multi-center trial to test the non-inferiority of EECSS compared with the SECSS, and to test the non-inferiority of 6 months duration compared with 12 months duration of clopidogrel therapy. Patients will be randomized in a two by two factorial manner according to the type of drug eluting stent (EECSS vs. SECSS) and the duration of dual anti-platelet therapy (6 months vs. 12 months). Randomization will also be stratified per hospital for the presence of DM and the presence of long lesions (lesion length ≥ 28mm)
Patient Enrollment: 1,372 patients enrolled at 17 centers in Korea.
Patient Follow-Up: Clinical follow-up will occur at 1, 3, and 9 months, and at 1, 2, 3, 4, and 5 years. Investigator or designee may conduct follow-up as telephone contacts or office visits.
Primary Endpoint
Secondary Endpoint
Condition | Intervention | Phase |
Coronary Artery Disease |
Device: Everolimus-eluting stent (Xience or Promus) Device: Sirolimus-eluting stent (Cypher) Drug: 6-month clopidogrel therapy Drug: 12-month clopidogrel therapy |
Phase IV |
MedlinePlus related topics: | Aneurysms Coronary Artery Disease Heart Attack |
ChemIDplus related topics: | Everolimus Sirolimus Clopidogrel Clopidogrel Bisulfate |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions |
Estimated Enrollment: | 1466 |
Study Start Date: | June 2008 |
Estimated Study Completion Date: | June 2014 |
Estimated Primary Completion Date: | June 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
E6: Experimental
Everolimus-eluting stent 6-month clopidogrel therapy
|
Device: Everolimus-eluting stent (Xience or Promus)
Use everolimus-eluting stent in the treatment of coronary stenosis
Drug: 6-month clopidogrel therapy
Use clopidogrel for 6 months
|
S6: Active Comparator
Sirolimus-eluting stent 6-month clopidogrel therapy
|
Device: Sirolimus-eluting stent (Cypher)
Use sirolimus-eluting stent in the treatment of coronary stenosis
Drug: 6-month clopidogrel therapy
Use clopidogrel for 6 months
|
E12: Experimental
Everolimus-eluting stent 12-month clopidogrel therapy
|
Device: Everolimus-eluting stent (Xience or Promus)
Use everolimus-eluting stent in the treatment of coronary stenosis
Drug: 12-month clopidogrel therapy
Use clopidogrel for 12 months
|
S12: Active Comparator
Sirolimus-eluting stent 12-month clopidogrel therapy
|
Device: Sirolimus-eluting stent (Cypher)
Use sirolimus-eluting stent in the treatment of coronary stenosis
Drug: 12-month clopidogrel therapy
Use clopidogrel for 12 months
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
General Inclusion Criteria:
Angiographically Inclusion Criteria
General Exclusion Criteria:
Angiographic Exclusion Criteria
Contact: Kyung-Woo Park, MD, PhD | 82-2-2072-0244 | kwparkmd@snu.ac.kr |
Korea, Republic of, 28 Yongon Dong, Jongro Gu | |||||
Seoul National University Hospital | Not yet recruiting | ||||
Seoul, 28 Yongon Dong, Jongro Gu, Korea, Republic of, 110-744 | |||||
Contact: Kyung-Woo Park, MD, PhD 82-2-2072-0244 kwparkmd@snu.ac.kr |
Seoul National University Hospital |
Abbott |
Boston Scientific Corporation |
Study Chair: | Hyo-Soo Kim, MD, PhD | Seoul National University Hospital |
Study Chair: | Yangsoo Jang, MD, PhD | Yonsei University Medical Center |
Study Chair: | Jung-Han Yoon, MD, PhD | Yonsei Univercity Wonju hospital |
Study Chair: | Ahn Tae-Hoon, MD, PhD | Gachon Kil Medical Center |
Study Chair: | Hyun-Cheol Kwon, MD, PhD | Samsung Medical Center |
Study Chair: | In-Ho Chae, MD, PhD | Seoul National University Bundang Hospital |
Principal Investigator: | Young-Jin Choi, MD, PhD | Hallym University Medical Center |
Principal Investigator: | Kyoo-Rok Han, MD, PhD | Kandong Sacred heart Hospital |
Principal Investigator: | Si-Hoon Park, MD, PhD | Ewha Women's University Hospital |
Principal Investigator: | Myeong-Ho Chung, MD, PhD | Chonnam National University Hospital |
Principal Investigator: | Hyuk-Moon Kwon, MD, PhD | Yongdong Severance Hospital |
Principal Investigator: | Dong-Woon Chun, MD, PhD | National Health Insurance Corporation Ilsan Hospital |
Principal Investigator: | Byung-Ok Kim, MD, PhD | Inje University Sanggye Hospital |
Principal Investigator: | Do-Sun Lim, MD, PhD | Korea University Anam Hospital |
Principal Investigator: | Taek-Jong Hong, MD, PhD | Pusan National University Hospital |
Principal Investigator: | Woo-Young Chung, MD, PhD | Borame Hospital |
Principal Investigator: | Jae-Hun Chung, MD, PhD | Kangnam Sacred Heart Hospital |
Responsible Party: | Seoul National University Hospital ( Hyo-Soo, Kim ) |
Study ID Numbers: | EXCELLENT |
First Received: | June 15, 2008 |
Last Updated: | September 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00698607 |
Health Authority: | South Korea: Institutional Review Board |
|
|
|
|
|